138 related articles for article (PubMed ID: 30608334)
21. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
[TBL] [Abstract][Full Text] [Related]
22. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.
Oh KS; Lee JH; Yi KY; Lim CJ; Lee S; Park CH; Seo HW; Lee BH
Br J Pharmacol; 2015 May; 172(10):2618-33. PubMed ID: 25597918
[TBL] [Abstract][Full Text] [Related]
23. Urotensin II stimulates plasma extravasation in mice via UT receptor activation.
Vergura R; Camarda V; Rizzi A; Spagnol M; Guerrini R; Calo' G; Salvadori S; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):347-52. PubMed ID: 15526105
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
Camarda V; Spagnol M; Song W; Vergura R; Roth AL; Thompson JP; Rowbotham DJ; Guerrini R; Marzola E; Salvadori S; Cavanni P; Regoli D; Douglas SA; Lambert DG; Calò G
Br J Pharmacol; 2006 Jan; 147(1):92-100. PubMed ID: 16273120
[TBL] [Abstract][Full Text] [Related]
25. Role of urotensin II and its receptor in health and disease.
McDonald J; Batuwangala M; Lambert DG
J Anesth; 2007; 21(3):378-89. PubMed ID: 17680191
[TBL] [Abstract][Full Text] [Related]
26. A new ligand for the urotensin II receptor.
Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
[TBL] [Abstract][Full Text] [Related]
27. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
28. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.
Johns DG; Ao Z; Naselsky D; Herold CL; Maniscalco K; Sarov-Blat L; Steplewski K; Aiyar N; Douglas SA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Oct; 370(4):238-50. PubMed ID: 15549273
[TBL] [Abstract][Full Text] [Related]
29. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
[TBL] [Abstract][Full Text] [Related]
30. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout.
Wang ZJ; Shi LB; Xiong ZW; Zhang LF; Meng L; Bu DF; Tang CS; Ding WH
Peptides; 2006 Apr; 27(4):858-63. PubMed ID: 16325305
[TBL] [Abstract][Full Text] [Related]
31. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
[TBL] [Abstract][Full Text] [Related]
32. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.
Bottrill FE; Douglas SA; Hiley CR; White R
Br J Pharmacol; 2000 Aug; 130(8):1865-70. PubMed ID: 10952676
[TBL] [Abstract][Full Text] [Related]
33. Central effects of urotensin-II following ICV administration in rats.
Gartlon J; Parker F; Harrison DC; Douglas SA; Ashmeade TE; Riley GJ; Hughes ZA; Taylor SG; Munton RP; Hagan JJ; Hunter JA; Jones DN
Psychopharmacology (Berl); 2001 Jun; 155(4):426-33. PubMed ID: 11441433
[TBL] [Abstract][Full Text] [Related]
34. Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs.
Soni H; Adebiyi A
J Endocrinol; 2013 Jun; 217(3):317-26. PubMed ID: 23554507
[TBL] [Abstract][Full Text] [Related]
35. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
[TBL] [Abstract][Full Text] [Related]
36. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
[TBL] [Abstract][Full Text] [Related]
37. Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.
Luci DK; Ghosh S; Smith CE; Qi J; Wang Y; Haertlein B; Parry TJ; Li J; Almond HR; Minor LK; Damiano BP; Kinney WA; Maryanoff BE; Lawson EC
Bioorg Med Chem Lett; 2007 Dec; 17(23):6489-92. PubMed ID: 17933531
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
[TBL] [Abstract][Full Text] [Related]
39. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
[TBL] [Abstract][Full Text] [Related]
40. Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain.
Gartlon JE; Ashmeade T; Duxon M; Hagan JJ; Jones DN
Eur J Pharmacol; 2004 Jun; 493(1-3):95-8. PubMed ID: 15189768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
